Sanofi (NASDAQ:SNY) Shares Purchased by Magnetar Financial LLC

Magnetar Financial LLC increased its holdings in shares of Sanofi (NASDAQ:SNY) by 1,153.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,506,286 shares of the company’s stock after purchasing an additional 2,306,286 shares during the quarter. Sanofi makes up approximately 2.6% of Magnetar Financial LLC’s portfolio, making the stock its 4th biggest position. Magnetar Financial LLC owned approximately 0.10% of Sanofi worth $121,605,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. POM Investment Strategies LLC purchased a new stake in Sanofi in the second quarter valued at approximately $25,000. Larson Financial Group LLC boosted its stake in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the period. Register Financial Advisors LLC purchased a new position in Sanofi during the 1st quarter worth $29,000. Johnson Financial Group Inc. acquired a new position in Sanofi in the fourth quarter valued at $31,000. Finally, Palisade Asset Management LLC purchased a new stake in shares of Sanofi in the first quarter valued at about $31,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SNY has been the topic of several recent research reports. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, StockNews.com upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

Shares of SNY stock opened at $57.63 on Monday. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a 50 day simple moving average of $54.34 and a 200-day simple moving average of $50.50. The company has a market cap of $145.96 billion, a price-to-earnings ratio of 28.96, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same quarter last year, the firm posted $0.95 EPS. The business’s revenue was up 7.8% compared to the same quarter last year. On average, equities analysts forecast that Sanofi will post 4.25 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.